Limits...
Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma.

Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, Bairey O - Br. J. Cancer (2002)

Bottom Line: The patients who expressed basic fibroblast growth factor had a significantly worse progression-free and overall survival than those who did not (P=0.003 and P=0.03 respectively), while patients expressing fibroblast growth factor receptor-1 were less likely to achieve complete remission than those lacking the receptor (33% vs 65%, P=0.047).There was no correlation of basic fibroblast growth factor staining with either serum basic fibroblast growth factor levels or microvessel count.Basic fibroblast growth factor serum levels did not change significantly after treatment These results suggest that non-Hodgkin's lymphoma specimens express basic fibroblast growth factor and its receptor (fibroblast growth factor receptor-1) and this expression is associated with poor patient outcome.

View Article: PubMed Central - PubMed

Affiliation: Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, 49100, Israel.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier progression-free survival (A) and overall survival (B) curves according to bFGF expression for 39 patients with NHL. bFGF expression was positive in lymphomas from nine patients (23%).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375415&req=5

fig2: Kaplan–Meier progression-free survival (A) and overall survival (B) curves according to bFGF expression for 39 patients with NHL. bFGF expression was positive in lymphomas from nine patients (23%).

Mentions: Staining of small lymphocytic lymphoma cells for bFGF (A), FGFR-1 (B).


Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma.

Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, Bairey O - Br. J. Cancer (2002)

Kaplan–Meier progression-free survival (A) and overall survival (B) curves according to bFGF expression for 39 patients with NHL. bFGF expression was positive in lymphomas from nine patients (23%).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375415&req=5

fig2: Kaplan–Meier progression-free survival (A) and overall survival (B) curves according to bFGF expression for 39 patients with NHL. bFGF expression was positive in lymphomas from nine patients (23%).
Mentions: Staining of small lymphocytic lymphoma cells for bFGF (A), FGFR-1 (B).

Bottom Line: The patients who expressed basic fibroblast growth factor had a significantly worse progression-free and overall survival than those who did not (P=0.003 and P=0.03 respectively), while patients expressing fibroblast growth factor receptor-1 were less likely to achieve complete remission than those lacking the receptor (33% vs 65%, P=0.047).There was no correlation of basic fibroblast growth factor staining with either serum basic fibroblast growth factor levels or microvessel count.Basic fibroblast growth factor serum levels did not change significantly after treatment These results suggest that non-Hodgkin's lymphoma specimens express basic fibroblast growth factor and its receptor (fibroblast growth factor receptor-1) and this expression is associated with poor patient outcome.

View Article: PubMed Central - PubMed

Affiliation: Institute of Hematology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, 49100, Israel.

Show MeSH
Related in: MedlinePlus